Mutational profile and benefit of gemtuzumab ...
Document type :
Compte-rendu et recension critique d'ouvrage
DOI :
Title :
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
Author(s) :
Fournier, Elise [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Duployez, Nicolas [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Ducourneau, Benoît [Auteur]
Raffoux, Emmanuel [Auteur]
Turlure, Pascal [Auteur]
Caillot, Denis [Auteur]
Thomas, Xavier [Auteur]
Marceau-Renaut, Alice [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Chantepie, Sylvain [Auteur]
Malfuson, Jean-Valère [Auteur]
Lemasle, Emilie [Auteur]
Cheok, Meyling [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Celli-Lebras, Karine [Auteur]
Guerin, Estelle [Auteur]
Terré, Christine [Auteur]
Lambert, Juliette [Auteur]
Pautas, Cécile [Auteur]
Dombret, Hervé [Auteur]
Castaigne, Sylvie [Auteur]
Preudhomme, Claude [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Boissel, Nicolas [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Duployez, Nicolas [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Ducourneau, Benoît [Auteur]
Raffoux, Emmanuel [Auteur]
Turlure, Pascal [Auteur]
Caillot, Denis [Auteur]
Thomas, Xavier [Auteur]
Marceau-Renaut, Alice [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Chantepie, Sylvain [Auteur]
Malfuson, Jean-Valère [Auteur]
Lemasle, Emilie [Auteur]
Cheok, Meyling [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Celli-Lebras, Karine [Auteur]
Guerin, Estelle [Auteur]
Terré, Christine [Auteur]
Lambert, Juliette [Auteur]
Pautas, Cécile [Auteur]
Dombret, Hervé [Auteur]
Castaigne, Sylvie [Auteur]
Preudhomme, Claude [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Boissel, Nicolas [Auteur]
Journal title :
Blood
Pages :
542-546
Publisher :
American Society of Hematology
Publication date :
2020-02-20
ISSN :
0006-4971
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Abstract Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic background and response to chemotherapy. Although molecular aberrations are routinely used to stratify AML patients into ...
Show more >Abstract Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic background and response to chemotherapy. Although molecular aberrations are routinely used to stratify AML patients into prognostic subgroups when receiving standard chemotherapy, the predictive value of the genetic background and co-occurring mutations remains to be assessed when using newly approved antileukemic drugs. In the present study, we retrospectively addressed the question of the predictive value of molecular events on the benefit of the addition of gemtuzumab ozogamicin (GO) to standard front-line chemotherapy. Using the more recent European LeukemiaNet (ELN) 2017 risk classification, we confirmed that the benefit of GO was restricted to the favorable (hazard ratio [HR], 0.54, 95% confidence interval [CI], 0.30-0.98) and intermediate (HR, 0.57; 95% CI, 0.33-1.00) risk categories, whereas it did not influence the outcome of patients within the adverse risk subgroup (HR, 0.93; 95% CI, 0.61-1.43). Interestingly, the benefit of GO was significant for patients with activating signaling mutations (HR, 0.43; 95% CI, 0.28-0.65), which correlated with higher CD33 expression levels. These results suggest that molecular aberrations could be critical for future differentially tailored treatments based on integrated genetic profiles that are able to predict the benefit of GO on outcome.Show less >
Show more >Abstract Acute myeloid leukemia (AML) is a highly heterogeneous disease both in terms of genetic background and response to chemotherapy. Although molecular aberrations are routinely used to stratify AML patients into prognostic subgroups when receiving standard chemotherapy, the predictive value of the genetic background and co-occurring mutations remains to be assessed when using newly approved antileukemic drugs. In the present study, we retrospectively addressed the question of the predictive value of molecular events on the benefit of the addition of gemtuzumab ozogamicin (GO) to standard front-line chemotherapy. Using the more recent European LeukemiaNet (ELN) 2017 risk classification, we confirmed that the benefit of GO was restricted to the favorable (hazard ratio [HR], 0.54, 95% confidence interval [CI], 0.30-0.98) and intermediate (HR, 0.57; 95% CI, 0.33-1.00) risk categories, whereas it did not influence the outcome of patients within the adverse risk subgroup (HR, 0.93; 95% CI, 0.61-1.43). Interestingly, the benefit of GO was significant for patients with activating signaling mutations (HR, 0.43; 95% CI, 0.28-0.65), which correlated with higher CD33 expression levels. These results suggest that molecular aberrations could be critical for future differentially tailored treatments based on integrated genetic profiles that are able to predict the benefit of GO on outcome.Show less >
Language :
Anglais
Popular science :
Non
ANR Project :
Collections :
Source :